Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved clinically meaningful reductions in blood Phe levels at month one of the open-label ...
— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...
Ponsegromab treatment led to sustained weight gain and GDF-15 suppression over 64 weeks in cancer-associated cachexia patients. Patients initially on placebo gained weight after switching to ...
Effects of UCHL1 on tolerogenic DC maturation and promotion of mregDC-Treg crosstalk to nullify anti–PD-L1 therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
A phase II clinical trial of ivonescimab (VEGFxPD-1 bispecific antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the 2026 ASCO ...
Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform ...
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer’s disease (AD) enrolled in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results